You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
|
|---|---|
| Published in |
European Journal of Cancer (1965), November 2013
|
| DOI | 10.1016/j.ejca.2013.10.006 |
| Pubmed ID | |
| Authors |
J.R. Brahmer, J.W. Lee, A.M. Traynor, M.M. Hidalgo, J.M. Kolesar, J.M. Siegfried, P.P. Guaglianone, J.D. Patel, M.D. Keppen, J.H. Schiller |
| Abstract |
The development of a rash has been retrospectively associated with increased response and improved survival when treated with erlotinib at the standard dose of 150 mg per day. The objective of this trial was to evaluate the association of the activity of erlotinib in the first-line setting in patients with advanced non-small-cell lung cancer (NSCLC) with the development of a tolerable rash via dose escalation of erlotinib or tumour characteristics. |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 5% |
| Netherlands | 1 | 2% |
| United Kingdom | 1 | 2% |
| Unknown | 40 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 20% |
| Other | 7 | 16% |
| Researcher | 6 | 14% |
| Student > Bachelor | 5 | 11% |
| Lecturer | 3 | 7% |
| Other | 5 | 11% |
| Unknown | 9 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 36% |
| Nursing and Health Professions | 4 | 9% |
| Agricultural and Biological Sciences | 3 | 7% |
| Business, Management and Accounting | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 4 | 9% |
| Unknown | 13 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2013.
All research outputs
#2,531,022
of 25,707,225 outputs
Outputs from European Journal of Cancer (1965)
#639
of 6,920 outputs
Outputs of similar age
#22,395
of 224,418 outputs
Outputs of similar age from European Journal of Cancer (1965)
#4
of 55 outputs
Altmetric has tracked 25,707,225 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,920 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 224,418 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.